Orkambi
Author: Zara Fulton
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Orkambi contains the combination of lumacaftor and ivacaftor, which has the dual mechanism of correcting and potentiating the function of CFTR protein, normalizing chloride conductance in patients with cystic fibrosis. The drug was first approved in the US in July 2015 for the treatment of cystic fibrosis in patients aged 12 years and older with two copies of the F508del mutation, and corresponding EU approval was granted in November 2015. It is marketed by Vertex alongside Kalydeco, which contains the single CFTR potentiator ivacaftor.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Orkambi : Cystic fibrosis
LIST OF FIGURES
9 Figure 1: Orkambi for cystic fibrosis – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Orkambi for cystic fibrosis
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Orkambi for cystic fibrosis
13 Figure 4: Orkambi sales for cystic fibrosis across the US and five major EU markets, by country, 2016–25
LIST OF TABLES
6 Table 1: Orkambi drug profile
7 Table 2: Orkambi Phase III data in cystic fibrosis
14 Table 3: Orkambi sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Arikayce 
Sign up to the